IP Library Granted Patent US 7,067,713
Granted Patent B2
US 7,067,713 · App. 10/181,704 · Granted Jun 27, 2006

C1 Inhibitor produced in the milk of transgenic non-human mammals

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,067,713
App. No.
10/181,704
Granted
Jun 27, 2006
Kind
B2
Abstract

The invention provides transgenic nonhuman mammals expressing C1 inhibitor in their milk. The C1 inhibitor is useful in treating patients with hereditary angioedema or patients requiring immunosuppression.

Claims (18)

1. A nonhuman mammal whose genome comprises a DNA segment encoding a C1 inhibitor heterologous to the mammal operably linked to at least one expression regulatory sequence from a gene that is preferentially expressed in mammary gland cells and a DNA segment encoding a signal peptide functional in mammary gland cells; wherein the DNA segment encoding the C1 inhibitor can be expressed in the mammary gland cells to produce C1 inhibitor in the milk of an adult form of said mammal or a female descendant thereof.

2. The nonhuman mammal of claim 1 , wherein the concentration of the C1 inhibitor in the milk is at least 1 mg/ml.

3. The nonhuman mammal of claim 1 , wherein the C1 inhibitor is human.

4. The nonhuman mammal of claim 1 , that is a mouse, rabbit, goat, sheep, porcine or bovine.

5. The nonhuman mammal of claim 4 , wherein the DNA segment is cDNA.

6. The nonhuman mammal of claim 4 , wherein the DNA segment is genomic.

7. The nonhuman mammal of claim 4 , wherein the DNA segment is a cDNA-genomic hybrid.

8. The nonhuman mammal of claim 1 , wherein the signal peptide is a C1 inhibitor signal peptide.

9. A method for providing C1 inhibitor comprising: recovering milk from the adult form of the transgenic nonhuman mammal or its female descendant of claim 1 .

10. The method of claim 9 , further comprising purifying the C1 inhibitor from the milk.

11. The method of claim 10 , wherein the C1 inhibitor is at least 95% pure.

12. The method of claim 11 , further comprising mixing the C1 inhibitor with a carrier.

13. Milk from a nonhuman transgenic mammal whose genome comprises a DNA segment encoding a C1 inhibitor heterologous to the mammal operably linked to at least one expression regulatory sequence from a gene that is preferentially expressed in mammary gland cells and a DNA segment encoding a signal peptide functional in mammary gland cells; wherein the DNA segment encoding the C1 inhibitor can be expressed in the mammary gland cells to produce C1 inhibitor in the milk of an adult form of said mammal or a female descendant thereof.

14. The milk of claim 13 , wherein the concentration of C1 inhibitor protein is at least 1 mg/ml.

15. The milk of claim 14 , wherein the C1 inhibitor has a functionality index of at least 0.9.

16. The method of claim 10 , where the purifying comprises: loading the milk onto a cationic exchange column under conditions in which the human C1 inhibitor binds to the column; eluting the human C1 inhibitor from the cationic exchange column; loading the eluate on an anionic exchange column under conditions in which the human C1 inhibitor binds to the column; eluting the human C1 inhibitor from the anionic exchange column; loading the eluate onto a metal ion exchange column under conditions in which residual contaminating proteins bind to the column; collecting eluate containing the human C1 inhibitor from the metal ion exchange column.

17. The method of claim 16 , wherein the sample further comprises rabbit C1 inhibitor; and the eluate from the metal ion exchange column has a higher ratio of human C1 inhibitor to rabbit C1 inhibitor than the sample.

18. The method of claim 17 , wherein the ratio is at least 500:1.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Jan 28, 2020
From: ORBIMED ROYALTY OPPORTUNITIES II, LP
To: PHARMING GROUP N.V.; PHARMING TECHNOLOGIES B.V.; PHARMING INTELLECTUAL PROPERTY B.V.; BROEKMAN INSTITUUT B.V.; PHARMING B.V.; PHARMING AMERICAS B.V.; PHARMING HEALTHCARE, INC.
Reel/Frame 051722/0304 →
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded May 16, 2017
From: PHARMING INTELLECTUAL PROPERTY B.V.
To: ORBIMED ROYALTY OPPORTUNITIES II, LP
Reel/Frame 042481/0139 →
SECURITY INTEREST Recorded Dec 7, 2016
From: PHARMING INTELLECTUAL PROPERTY B.V.
To: SILICON VALLEY BANK
Reel/Frame 040839/0865 →
RELEASE OF SECURITY INTEREST Recorded Feb 24, 2010
From: KING GEORGE HOLDINGS LUXEMBOURG IIA S.A.R.L.
To: PHARMING INTELLECTUAL PROPERTY B.V.
Reel/Frame 023985/0169 →
GRANT OF A SECURITY INTEREST IN GRANTOR'S (DEBTOR'S) OWNERSHIP RIGHTS TO GRANTEE (SECURED PARTY) Recorded Feb 27, 2006
From: PHARMING INTELLECTUAL PROPERTY B.V.
To: KING GEORGE HOLDINGS LUXEMBOURG IIA S.A.R.L.
Reel/Frame 017215/0991 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2002
From: NUIJENS, JAN HENRICUS; VAN VEEN, HENRICUS ANTONIUS; PIEPER, FRANK ROBERT; HEUS, JORIS JAN
To: PHARMING INTELLECTUAL PROPERTY B.V.
Reel/Frame 013279/0043 →